Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Tango Therapeutics Inc. — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.95B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 40 Days and Tango Therapeutics Inc. for 0 Days on average.
| EMLC | TNGX | |
|---|---|---|
Market Cap | $4.95B | $3.75B |
Volume | 2,930,860 | 9,619,106 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $32.90 |
52-Week Low | $24.53 | $7.50 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.92, up 0.24% on the day, but technical indicators signal a bearish trend with the stock recently hitting a 52-week low. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though some analysts see value in emerging market local currency bonds. Recent dividends of $0.14 and $0.13 were declared for October and August 2026.
Outlook remains cautious as dollar strength pressures emerging market currencies, though diversification benefits and yield potential offer long-term opportunities. Key risks include currency volatility and rising global bond yields, while institutional sentiment appears mixed with technical weakness dominating near-term price action.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
